Prosecution Insights
Last updated: November 20, 2026

Janssen Sciences Ireland Unlimited Company

Technology area: Biotechnology & Pharmaceuticals

5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days

Analysis

Janssen Sciences Ireland Unlimited Company has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 5 distinct examiners and 5 distinct art units, indicating separate reported examination settings.

LANKFORD JR, LEON B is the busiest examiner, with 1 pending matter. The data does not show repeated assignment to an examiner or art unit, so no portfolio-wide examiner pattern is established. Practitioners should evaluate each action in its own technical and examination context.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

5
Total Pending OAs
4
Non-Final OAs
0
Final Rejections
1
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
4
Medium (80%)
1
Easy (20%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only3 (60%)
§112 only1 (20%)
Double-patenting + other1 (20%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

5
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

50 h
Manual time on pending OAs
10 h
Time saved (low, 20%)
18 h
Time saved (mid, 35%)
0.4 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
LANKFORD JR, LEON B 1 70.1% +31.4%
AGGARWAL, SAHIL CHANDER 1 66.7% +0.0%
FERGUSON, JALISA HOLMES 1 63.4% +39.5%
RAMACHANDRAN, UMAMAHESWARI 1 54.8% +53.5%
GURLEY, JAMI MICHELLE 1 50.0% +19.4%

Interview Candidates (4)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
17596538 Recombinant Interleukin 12 Construct and Uses Thereof GURLEY, JAMI MICHELLE 21d
18858037 FREEZE DRIED COMPOSITIONS LANKFORD JR, LEON B —
18550323 ANTIBACTERIAL COMPOUNDS FERGUSON, JALISA HOLMES —
17621759 METHODS OF TREATING HIV IN PEDIATRIC PATIENTS WITH RILPIVIRINE RAMACHANDRAN, UMAMAHESWARI —

Top Art Units

Art UnitApps
1657 1
1623 1
1626 1
1627 1
1647 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18858037 FREEZE DRIED COMPOSITIONS LANKFORD JR, LEON B 1657 §103 Non-Final OA — Pending Oct 18, 2024
18705114 IMIDAZOPYRIDINE AMIDES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS AGGARWAL, SAHIL CHANDER 1623 §112 Non-Final OA — Pending Apr 26, 2024
18550323 ANTIBACTERIAL COMPOUNDS FERGUSON, JALISA HOLMES 1626 §112DP Non-Final OA — Pending Sep 13, 2023
17621759 METHODS OF TREATING HIV IN PEDIATRIC PATIENTS WITH RILPIVIRINE RAMACHANDRAN, UMAMAHESWARI 1627 §103Other Non-Final OA — Pending Dec 22, 2021
17596538 Recombinant Interleukin 12 Construct and Uses Thereof GURLEY, JAMI MICHELLE 1647 §103 Non-Final OA 21d Pending Dec 13, 2021

Managing Janssen Sciences Ireland Unlimited Company's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Janssen Sciences Ireland Unlimited Company have?

Janssen Sciences Ireland Unlimited Company has 5 pending office actions as of November 2026, spread across 5 art units and 5 examiners.

Which USPTO examiner handles the most Janssen Sciences Ireland Unlimited Company applications?

Leon B Lankford Jr. has the most, with 1 of Janssen Sciences Ireland Unlimited Company's pending office actions.

What technology area are Janssen Sciences Ireland Unlimited Company's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month